Logo

BMS Presents Results of Deucravacitinib in Two P- III Trials for Moderate to Severe Plaque Psoriasis at AAD2021

Share this

BMS Presents Results of Deucravacitinib in Two P- III Trials for Moderate to Severe Plaque Psoriasis at AAD2021

Shots:

  • The two P-III POETYK PSO-1 and POETYK PSO-2 trials evaluating deucravacitinib (6mg- qd) vs PBO & Otezla (30mg- bid) @16wks. and vs Otezla @24wks. in 666 and 1-020 patients with the mod. to sev. plaque psoriasis respectively
  • The trials met its co-1EPs & 2EPs i.e @16wks.- PASI 75 (58.7% and 53.6%) vs (12.7% and 9.4%)& (35.1% and 40.2%) and @24wks. (69.0% and 59.3%) vs (38.1% and 37.8%)- patients who achieved PASI 75- continued treatment with deucravacitinib (82.5% and 81.4%) and maintained it @52wks. respectively
  • sPGA 0/1 response @16wks. (53.6% and 50.3%) vs (7.2% and 8.6%) & (32.1% and 34.3%) and @24wks (58.4% and 50.4%) vs (31.0% and 29.5%) respectively

  Ref: BMS | Image: BMS 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions